ImpriMed is excited to showcase its latest research at the AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals. Join us for Poster Session B on Wednesday, March 12, from 7:15 to 8:45 PM, where we will present: "A Study on the Relationship Between Ex Vivo Drug Sensitivity and Clinical Outcome of Acute Lymphoblastic Leukemia." We look forward to sharing our findings and engaging in meaningful discussions. See you there!
Click here to go to the official event page →ImpriMed is excited to showcase its latest research at the AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals. Join us for Poster Session B on Wednesday, March 12, from 7:15 to 8:45 PM, where we will present: "A Study on the Relationship Between Ex Vivo Drug Sensitivity and Clinical Outcome of Acute Lymphoblastic Leukemia." We look forward to sharing our findings and engaging in meaningful discussions. See you there!
Conference Cochairs:
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts
Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio
Peter Horak, German Cancer Research Center, Heidelberg, Germany
Alice Soragni, University of California, Los Angeles, California
Precision medicine applied to oncology aims to match each patient to the right therapy. Heretofore, genomics has been the main tool in performing precision medicine. Yet, many cancer patients lack actionable alterations as there is a limited set of highly predictive biomarkers to accurately match patients to effective therapies. There is a need to extend the benefits of precision medicine to a larger proportion of cancer patients. Therefore, additional strategies need to be explored. One important approach is functional precision medicine, a strategy by which living patient tumor cells are exposed to therapies and signals measured to predict clinical response. The goal of this AACR Special Conference is to share experiences among those in the genomics and functional precision oncology arenas, to accelerate the progress toward routine clinical adoption of combined approaches in the oncology clinic. At this exciting program in Boston we will share technical, clinical, and logistical experiences, as well as our understanding of the barriers to widespread adoption of genomic and functional precision medicine in the treatment of the cancer patient, and how these approaches might be combined to provide more powerful tools than either alone.
